Free Trial
NASDAQ:SNOA

Sonoma Pharmaceuticals 2/8/2024 Earnings Report

Sonoma Pharmaceuticals logo
$4.06 +0.02 (+0.37%)
As of 12:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sonoma Pharmaceuticals EPS Results

Actual EPS
-$0.06
Consensus EPS
-$0.21
Beat/Miss
Beat by +$0.15
One Year Ago EPS
N/A

Sonoma Pharmaceuticals Revenue Results

Actual Revenue
$3.14 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sonoma Pharmaceuticals Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Sonoma Pharmaceuticals' next earnings date is estimated for Thursday, November 6, 2025, based on past reporting schedules.

Conference Call Resources

Sonoma Pharmaceuticals Earnings Headlines

Turn $1K into $50K with This DeFi Gem
Bitcoin grabs headlines, but smart money likes this token My research team has identified the token positioned at the absolute center of this incoming capital flood— a project so fundamentally essential to the crypto ecosystem that institutional investors simply cannot ignore it.tc pixel
See More Sonoma Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sonoma Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sonoma Pharmaceuticals and other key companies, straight to your email.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals (NASDAQ:SNOA) is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases. This approach is designed to enhance efficacy while minimizing skin irritation. The company’s lead product, Azclear® Foaming Gel, leverages azelaic acid to address papulopustular rosacea, and is complemented by additional prescription formulations and a suite of over-the-counter cleansers and medicated washes targeting acne-prone skin.

Headquartered in Santa Rosa, California, Sonoma Pharmaceuticals distributes its dermatology portfolio through physician offices, retail pharmacies and online channels across the United States. Under the leadership of President and Chief Executive Officer Mark D. Sirgo, the company is advancing its clinical pipeline and exploring strategic collaborations to expand its product offerings and reach new patient populations.

View Sonoma Pharmaceuticals Profile

More Earnings Resources from MarketBeat